Cantabio Pharmaceuticals to Present Update from Its DJ-1 Protein Targeting Therapeutic Program for the Treatment of Parkinson’s Disease at Advances in Alzheimer’s and Parkinson’s Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy
SAN FRANCISCO, CA–(Marketwired – January 22, 2018) – Cantabio Pharmaceuticals Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Cantabio’s CEO, will present results of the company’s DJ-1 protein targeting small molecule pharmacological chaperone therapeutic program at the Advances in Alzheimer’s and Parkinson’s Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy, March 15 – 18, 2018.
Loss of DJ-1 protein function has been linked to the onset of a variety of diseases, such as Parkinson’s disease, Alzheimer’s disease, stroke, amyotrophic lateral sclerosis, chronic obstructive pulmonary disease and type II diabetes. The DJ-1 protein is considered to be one of the primary therapeutic targets for Parkinson’s disease, as it is genetically linked to the onset of familial Parkinson’s disease.
The presentations will describe the positive biological activity in cellular and in vivo models of Parkinson’s disease of Cantabio’s novel DJ-1 protein targeting small molecule drug candidates and novel findings relating to the mechanism of loss of function of DJ-1 in disease conditions.
The data will be presented on:
March 18, 8:50-9:10 CET – Symposium 27 – Emerging Treatments in PD; Abstract Number AAT18-0226
The lecture is titled, “Identification and optimization of a novel DJ-1 targeting small molecule with protective activity in Parkinson’s disease relevant cellular and in vivo models“.
March 17, 8:00-18:00 CET — C01.b. C1.b Disease Mechanisms, Pathophysiology: LRKK2, parkin, PINK1, DJ-1; Abstract Number 145
The poster is titled, “DJ-1 protein aggregates into b-sheeted oligomers and fibrillar aggregates which results in loss of its native functions”.
The presentations are co-authored by researchers from Purdue University (USA), Novalix SAS (France), University of Antioquia (Colombia), and the Hungarian Academy of Sciences.
Cantabio’s CEO, Dr. Gergely Toth said: “We are excited to share an update on the positive progress of our DJ-1 protein targeting pharmacological chaperone program at this major conference, as well as new insights into the mechanism of loss of function of DJ-1 during disease onset and progression. These results from our in-house and collaborators’ research demonstrate our growing confidence in our DJ-1 targeting therapeutic candidates’ excellent potential as disease modifying therapeutics for PD and AD.”
Cantabio is focused on bringing novel, first in class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s, Parkinson’s and oxidative stress. More information is available at www.cantabio.com.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Thomas Sawyer, Ph.D., M.B.A.
Cantabio Pharmaceuticals, Inc.
Investors and Media Relations: